Top Page
Genus plc
(LSE:GNS)
Genus plc (GNS) vs. S&P 500 (SPY)
Genus plc Business Overview & Revenue Model
Genus plc Financial Statement Overview
| Breakdown | ||||
| Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 | Jun 2020 |
|---|---|---|---|---|
| Income Statement | Total Revenue | |||
| 668.80M | 689.70M | 593.40M | 574.30M | 551.40M | Gross Profit |
| 178.70M | 239.30M | 226.00M | 232.20M | 211.60M | EBIT |
| 6.40M | 40.50M | 56.60M | 61.50M | 45.40M | EBITDA |
| 73.70M | 87.50M | 79.80M | 82.30M | 68.00M | Net Income Common Stockholders |
| 7.90M | 33.30M | 40.90M | 47.30M | 35.30M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
| 42.50M | 36.30M | 38.80M | 46.00M | 41.30M | Total Assets |
| 1.03B | 1.01B | 1.02B | 851.00M | 855.40M | Total Debt |
| 291.20M | 232.10M | 223.80M | 151.60M | 143.90M | Net Debt |
| 248.70M | 195.80M | 185.00M | 105.60M | 102.60M | Total Liabilities |
| 485.00M | 440.30M | 445.80M | 354.40M | 360.90M | Stockholders Equity |
| 548.20M | 569.40M | 578.50M | 498.10M | 495.50M |
| Cash Flow | Free Cash Flow | |||
| 5.10M | 15.20M | -7.80M | 38.80M | 35.50M | Operating Cash Flow |
| 29.80M | 50.40M | 34.30M | 67.50M | 60.10M | Investing Cash Flow |
| -19.30M | -30.90M | -67.20M | -46.70M | -25.00M | Financing Cash Flow |
| -2.80M | -18.20M | 21.90M | -14.20M | -23.10M |
Genus plc Technical Analysis
Genus plc Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
82 Outperform | £13.98B | 10.02 | 13.06% | 3.35% | 1.64% | 44.38% | |
75 Outperform | £8.94B | 31.08 | 16.90% | 0.94% | 11.94% | 20.48% | |
67 Neutral | £1.15B | 147.63 | -0.73% | 1.83% | -0.22% | -111.98% | |
63 Neutral | £3.66B | 23.10 | 6.84% | 4.16% | -3.92% | -7.32% | |
52 Neutral | £292.49M | ― | -2.48% | 5.15% | -16.16% | 80.50% | |
48 Neutral | $6.27B | 1.17 | -48.19% | 2.68% | 17.28% | 1.24% |
Genus plc Earnings Call Summary
Genus plc Corporate Events
Genus plc, a company listed on the London Stock Exchange, has announced the vesting of share awards granted to Jim Low, a member of its Executive Leadership Team. These awards were initially granted to compensate for remuneration forfeited due to his resignation from a previous employer. On March 31, 2025, 10,680 shares vested, and Jim Low sold 4,350 shares to cover tax liabilities, retaining 6,330 shares. This transaction reflects Genus’s commitment to retaining key talent and ensuring competitive compensation packages, which may impact its operational stability and stakeholder confidence.
Genus PLC has announced a change in the voting rights held by BlackRock, Inc., which now holds a total of 5.04% of the company’s voting rights. This change, effective from April 1, 2025, reflects BlackRock’s increased stake in Genus PLC, potentially impacting the company’s shareholder dynamics and market perception.
Genus plc has appointed Andy Russell as the new Chief Financial Officer, effective August 1, 2025, succeeding Alison Henriksen. Russell brings extensive experience from Smith & Nephew plc, where he held senior finance roles. His appointment is expected to support Genus’s strategic priorities and growth opportunities, enhancing its position in the animal genetics industry.
Genus plc has announced that as of 28 February 2025, its issued share capital comprises 66,036,538 ordinary shares with voting rights, and none are held in treasury. This information is crucial for shareholders to calculate their interests or changes in interests under the FCA’s Disclosure Guidance and Transparency Rules.
Genus plc announced the vesting of 44,933 nil-cost options granted over ordinary shares, with CEO Jorgen Kokke selling 19,967 shares to cover tax liabilities and retaining 24,966 shares. This transaction highlights the company’s ongoing management of executive compensation and shareholding strategies, reflecting its commitment to aligning leadership interests with shareholder value.
Genus plc reported a strong financial performance for the first half of the fiscal year, with a 19% increase in adjusted operating profit and a 21% rise in adjusted profit before tax. The company achieved significant cash generation and maintained its interim dividend. Strategic progress was noted in the porcine sector with new customer wins in China and advancements in gene editing technology, while the bovine sector saw improvements through the Value Acceleration Programme. Genus expects continued growth, although geopolitical and currency challenges remain.
Genus plc has announced the retirement of Professor Jason Chin from its Board of Directors, effective May 2025, as he assumes a new role at the Ellison Institute of Technology. Professor Chin, who has served as a Non-Executive Director and Chairman of the Scientific Advisory Board, will continue as a member of the advisory board. The company has begun searching for his successor, highlighting the importance of his contributions to Genus’s scientific advancements.
Genus plc has announced that as of January 31, 2025, its issued share capital is composed of 66,036,295 ordinary shares, each with voting rights. There are no shares held in treasury, and all shares possess identical voting rights. This information is useful for shareholders to determine their interests in Genus under the FCA’s Disclosure Guidance and Transparency Rules.
Genus plc has reported a strong performance in the first half of FY25, surpassing expectations with a projected Group adjusted profit before tax of at least £35 million. The company’s innovative PRRS Resistant Pig programme is progressing through regulatory processes, and the Board anticipates adjusted profit for FY25 to reach the top-end of market expectations, despite an expected currency headwind.